Cargando…
Androstenedione and Follicle-Stimulating Hormone Concentration Predict the Progression of Frailty Syndrome at One Year Follow-Up in Patients with Localized Breast Cancer Treated with Aromatase Inhibitors
Background: The standard treatment in postmenopausal women with estrogen- and progesterone-positive localized breast cancer consists of aromatase inhibitors (AROi). The ability of AROi to promote or worsen frailty syndrome over time and the relationship with changes in gonadal hormones concentration...
Autores principales: | García-Sánchez, Javier, Mafla-España, Mayra Alejandra, Torregrosa, María Dolores, Cauli, Omar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312841/ https://www.ncbi.nlm.nih.gov/pubmed/35884939 http://dx.doi.org/10.3390/biomedicines10071634 |
Ejemplares similares
-
Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study
por: García-Sánchez, Javier, et al.
Publicado: (2022) -
Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy
por: Mafla-España, Mayra Alejandra, et al.
Publicado: (2023) -
Plasma Aromatase Activity Index, Gonadotropins and Estrone Are Associated with Frailty Syndrome in Post-Menopausal Women with Breast Cancer
por: García-Sánchez, Javier, et al.
Publicado: (2022) -
Analysis of Frailty Syndrome in Men with Metastatic Prostate Cancer: A Scoping Review
por: Mafla-España, Mayra Alejandra, et al.
Publicado: (2023) -
Comparison of Frailty Criteria, Cognitive Function, Depressive and Insomnia Symptoms in Men with Localized and Advanced Prostate Cancer under Androgen Deprivation Therapy
por: Mafla-España, Mayra Alejandra, et al.
Publicado: (2023)